Filing Details
- Accession Number:
- 0001209191-18-056910
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-11-02 16:02:48
- Reporting Period:
- 2018-02-09
- Accepted Time:
- 2018-11-02 16:02:48
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1337553 | Aerie Pharmaceuticals Inc | AERI | Biological Products, (No Disgnostic Substances) (2836) | 203109565 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1590001 | C. Casey Kopczynski | C/O Aerie Pharmaceuticals, Inc. 4301 Emperor Blvd., Suite 400 Durham NC 27703 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-02-09 | 3,251 | $0.40 | 139,768 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-02-09 | 25 | $52.55 | 139,743 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2018-11-01 | 3,208 | $52.99 | 136,535 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-11-01 | 7,792 | $54.22 | 128,743 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | F | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2018-02-09 | 3,251 | $0.00 | 3,251 | $0.40 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2018-02-19 | No | 4 | M | Direct |
Footnotes
- The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions pursuant to the reporting person's Rule 10b5-1 plan at prices ranging from $52.61 to $53.58, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions pursuant to the reporting person's Rule 10b5-1 plan at prices ranging from $53.90 to $54.48, inclusive.
- This option is fully vested and exercisable.
Billionaire Hedge Funds
